AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
New analysis points to 2004 finish for phase III study of pemtumomab.(Brief Article)
2002 SEP 26 - (NewsRx.com & NewsRx.net) -- Antisoma, plc, the U.K.-based biopharmaceutical company developing new drugs for cancer, announced the result of an independent statistical analysis refining the predicted completion time for its pivotal phase III trial of pemtumomab in ovarian cancer.
The analysis shows that completion of the SMART (study of monoclonal antibody radioimmunotherapy) trial is most likely to take place during the second half of 2004.
The predicted completion time, based on the aggregated death rate in the study to date, was reported by the SMART independent data safety monitoring committee (DSMC), who also reported that there are no safety data or concerns that warrant changes in the conduct of the study at the present time.
The SMART study compares survival of patients receiving standard treatment plus pemtumomab with that of patients receiving standard treatment alone. The trial will finish once there have been a total of 116 deaths across both groups.
The study also includes an interim analysis, which is expected to take place ...
- Press Release: New analysis points to 2004 finish for Phase III study of...
- News wire article from: Asia Africa Intelligence Wire August 20, 2002 700+ words
...completion time for its pivotal Phase III trial of pemtumomab in ovarian cancer. The analysis...receiving standard treatment plus pemtumomab with that of patients receiving...demonstrates a survival benefit with pemtumomab, the study will form the basis...
- PRESS RELEASE: Recruitment to Phase III study of Antisoma's lead product...
- News wire article from: Chemical Business Newsbase June 12, 2001 700+ words
...announces its intention to extend recruitment to the Phase III SMART study of pemtumomab (formerly known as Theragyn) in the treatment...cancer patients with Yttrium-90 radiolabelled pemtumomab, in addition to current standard care, demonstrates...
- RECRUITMENT TO PHASE III STUDY OF ANTISOMA'S LEAD PRODUCT PEMTUMOMAB EXTENDED...
- Press release article from: PR Newswire June 6, 2001 700+ words
...extend recruitment to the Phase III SMART study of pemtumomab (formerly known as Theragyn...Yttrium-90 radiolabelled pemtumomab, in addition to current standard...potentially some greater effect from pemtumomab. At this stage it is not...
- Antisoma plc, of London, saw it shares rise by 4.75 pence to 45.5 pence Friday...
- Newspaper article from: BioWorld International July 23, 2003 700+ words
...shares rise by 4.75 pence to 45.5 pence Friday when the company announced revised end dates for its Phase III trial of R1549 (formerly pemtumomab) in the treatment of ovarian cancer. The independent safety monitoring committee said the trial...
- First Findings From Pemtumomab Gastric Cancer Trial Presented.
- Press release article from: PR Newswire October 24, 2002 700+ words
...cancer complements our phase III study in ovarian cancer...commercial potential of pemtumomab. We look forward...Antisoma's lead product pemtumomab is designed for the...recruitment in its pivotal phase III study of pemtumomab in ovarian cancer...
- Antisoma Announces Amendments to Pemtumomab Licensing Agreement With Abbott...
- Press release article from: PR Newswire January 4, 2002 700+ words
...confidence in the potential of pemtumomab and this new agreement allows...the lead product candidate, pemtumomab, which was licensed from...Fund and is currently in a Phase III study as adjuvant treatment...information about Antisoma. Pemtumomab Pemtumomab is based on a mouse...
- ANTISOMA'S LEAD PRODUCT, PEMTUMOMAB (FORMERLY KNOWN AS THERAGYN) GRANTED...
- Press release article from: PR Newswire June 1, 2001 700+ words
...the lead product candidate, pemtumomab, which was licensed from the...Fund and is currently in a Phase III study as adjuvant treatment...Current stage of development pemtumomab Ovarian cancer Phase III Gastric cancer Phase II Therex...
- Press Release: Antisoma reaches patient recruitment target in pivotal trial of...
- News wire article from: Asia Africa Intelligence Wire September 30, 2002 700+ words
...recruitment in its pivotal Phase III study of pemtumomab in ovarian cancer. Four hundred...ovarian cancer who receive pemtumomab in addition to standard treatment...survival benefit seen with pemtumomab in an earlier Phase II trial...
- Antisoma Reaches Patient Recruitment Target in Pivotal Trial Of Lead Cancer...
- Press release article from: PR Newswire September 30, 2002 700+ words
...its pivotal phase III study of pemtumomab in ovarian cancer...benefit seen with pemtumomab in an earlier...substantial phase III trial is a major...lead product pemtumomab is designed...well as the phase III study in ovarian...
- Antisoma's Lead Product, Pemtumomab (Formerly Known as Theragyn) Granted...
- Press release article from: PR Newswire June 1, 2001 700+ words
...the lead product candidate, pemtumomab, which was licensed from the...Fund and is currently in a Phase III study as adjuvant treatment...Current stage of development pemtumomab Ovarian cancer Phase III Gastric cancer Phase II Therex...
Source: HighBeam Research, New analysis points to 2004 finish for phase III study of...